Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

GeoVax Labs, Inc. GOVX

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.5M
▼ 37.1% YoY
$-21.5M
$-21.5M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 2.5M
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2025 · Revenue 2.5 · Net income -21.5
2M3M-10M-20M
2007201020132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−862 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -869.3% · Net -862.3%
-5000%-10000%-15000%
200720162025
ROE
FY2025 · ROE -483.8%
-200%-400%
200720162025
Three returns, three denominators.

Each USD of equity lost 484 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -21.5
-10M-20M
200720162025

Total assetsUSD 6.3M
EquityUSD 3.8M
CashUSD 3.1M
Current ratio2.74×

Equity funds 60% of total assets.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
GOVX, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B0.00.00.00.00.00.00.00.00.00.0◌◌◌◌◌◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
Income tax $B◌◌◌◌0.00.00.00.00.00.00.00.00.00.00.0◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌−0.0◌−0.0−0.0−0.0◌−0.0−0.0−0.0◌◌
EPS, diluted $◌◌◌◌−3.04−2.14−781.87−15610.33−0.03−0.08−0.08−0.10−0.11−0.12−0.15−0.18−0.22◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————————
ROE %−483.8−462.3−160.5−90.6−266.6————−452.8−228.8−148.8−124.2−230.3−184.8−98.5−101.8−139.2−160.2
Shares out B0.000.010.000.030.010.000.000.000.110.060.030.030.000.000.020.02◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 68 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007

Share this section

Download image